The FDA has approved Madrigal Pharmaceuticals’ resmetirom, sold under the brand name Rezdiffra, as the first therapy for MASH, also…
Browsing: Clinical Updates
The AGA supports the use of FMT for preventing recurrent Clostridium difficile infection (CDI) but does not recommend it for…
Conducted by the Regenstrief Institute and Indiana University School of Medicine, the study involved over 21,000 average-risk patients across 186…
Key Points The PROFILE clinical trial found that early and aggressive immunosuppressive therapy using tumor necrosis factor (TNF) inhibitors is…
Key Points: A large-scale cohort study has confirmed that low-dose aspirin use is associated with a reduced risk of colorectal…
Key Insights: The article, published JAMA Network Open, reports on a study led by Frederik E. Juul, M.D., Ph.D., from…
Key Insights: The article presents a clinical practice update on polypectomy techniques, authored by Drs. Andrew Copeland, Charles Kahi, Cynthia…
Current Challenges: AGA identifies barriers to IBD care, including insurer-mandated restrictions and prohibitive drug costs, affecting millions of Americans with…
Study Findings: 10% of at-home fecal immunological tests (FIT) for colorectal cancer (CRC) screening were unsatisfactory, primarily due to specimen…
Survodutide Efficacy: Achieved “statistically significant improvement” in 83% of patients with metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis. Phase 2…